## P02-280 - THE COMBINATION OF AMISULPIRIDE AND CLOZAPINE FOR THE TREATMENT OF TREATMENT-RESISTANT SCHIZOPHRENIA

**C. Istikoglou**<sup>1</sup>, D. Foutsitzis<sup>1</sup>, F. Papouli<sup>1</sup>, N. Polonifis<sup>1</sup>, P. Kanellos<sup>1</sup>, G. Theodorakopoulos<sup>1</sup>, J. Kogeorgos<sup>1</sup>, D. Vlissides<sup>2</sup>, K. Michelidakis<sup>2</sup>, T. Salla<sup>1</sup>

<sup>1</sup>Psychiatric Department, 'Konstantopouleio' General Hospital of Nea Ionia, <sup>2</sup>Psychiatric Department, 'Asklepeio' General Hospital of Voula, Athens, Greece

**Objectives:** Treatment-resistant schizophrenia is an old term, describing the form of schizophrenia that does not respond to a treatment dose of Chloropromazine, equal to 1,5 gr.

**Methods:** 20 (n=20) patients have been studied, that were diagnosed with schizophrenia, and did not respond to any combination of typical or non-typical anti-psychotic drugs. These patients were 19-62 years of age, and were administered the BPRS and PANSS scales at start of the examination or the hospitalization, and during the 1<sup>st</sup>, 3<sup>rd</sup>, and 6<sup>th</sup> month evaluation. The said patients were treated with a combination of Amisulpiride, and Clozapine.

**Results:** The patients received a dosage range of 400-1200mg for the Amisulpiride, and 300-900mg for the Clozapine. 18 patients (90%) responded to this treatment, and showed an improvement in the BPRS and PANSS scales, from the 1<sup>st</sup> month of treatment using a combination of Amisulpiride-Clozapine. Later, during the 3<sup>rd</sup> month of treatment, one of the patients discontinued the treatment, as she presented leucopenia (white cell count: 3250). The discontinuation of Clozapine treatment was decided. Clozapine was replaced by 20mg Olanzapine.

**Conclusions:** Despite the fact that the sample of patients was very small (n=20), it seems that the combination of Amisulpiride and Clozapine is effective for the treatment of patients showing resistance in pharmaceutical treatment and the combination of typical and non-typical neuroleptics.